R
Robert R. Bahnson
Researcher at Ohio State University
Publications - 123
Citations - 6397
Robert R. Bahnson is an academic researcher from Ohio State University. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 37, co-authored 123 publications receiving 6112 citations. Previous affiliations of Robert R. Bahnson include University of Miami & University of Iowa.
Papers
More filters
Journal ArticleDOI
Prostate cancer. Clinical practice guidelines in oncology.
James L. Mohler,Robert R. Bahnson,Barry Boston,J. Erik Busby,Anthony V. D'Amico,James A. Eastham,Charles Arthur Enke,Daniel J. George,Eric M. Horwitz,Robert P. Huben,Philip W. Kantoff,Mark H. Kawachi,Michael Kuettel,Paul H. Lange,Gary R. MacVicar,Elizabeth R. Plimack,Julio M. Pow-Sang,Mack Roach,Eric M. Rohren,Bruce J. Roth,Dennis C. Shrieve,Matthew R. Smith,Sandy Srinivas,Przemyslaw Twardowski,Patrick C. Walsh +24 more
Journal ArticleDOI
Prostate Cancer, Version 1.2016
James L. Mohler,Andrew J. Armstrong,Robert R. Bahnson,Anthony V. D'Amico,Brian J. Davis,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Michael E. Hurwitz,Christopher J. Kane,Mark H. Kawachi,Michael Kuettel,Richard T. Lee,Joshua J. Meeks,David F. Penson,Elizabeth R. Plimack,Julio M. Pow-Sang,David Raben,Sylvia Richey,Mack Roach,Stan Rosenfeld,Edward M. Schaeffer,Ted A. Skolarus,Eric J. Small,Guru Sonpavde,Sandy Srinivas,Seth A. Strope,Jonathan D. Tward,Dorothy A. Shead,Deborah A. Freedman-Cass +31 more
TL;DR: This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
Journal ArticleDOI
Clinical use of Prostate Specific Antigen in Patients with Prostate Cancer
TL;DR: It is concluded that the serum prostate specific antigen assay is most useful clinically to monitor the response to therapy of prostate cancer patients.
Journal ArticleDOI
Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology
James L. Mohler,Philip W. Kantoff,Andrew J. Armstrong,Robert R. Bahnson,Michael B. Cohen,Anthony V. D'Amico,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Christopher J. Kane,Mark H. Kawachi,Michael Kuettel,Timothy M. Kuzel,Richard T. Lee,Arnold W. Malcolm,David Miller,Elizabeth R. Plimack,Julio M. Pow-Sang,David Raben,Sylvia Richey,Mack Roach,Eric M. Rohren,Stan Rosenfeld,Edward M. Schaeffer,Eric J. Small,Guru Sonpavde,Sandy Srinivas,Cy A. Stein,Seth A. Strope,Jonathan D. Tward,Dorothy A. Shead,Maria Ho +33 more
TL;DR: Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations.
Journal ArticleDOI
Prostate cancer early detection, Version 2.2016: Featured updates to the NCCN guidelines
Peter R. Carroll,J. Kellogg Parsons,Gerald L. Andriole,Robert R. Bahnson,Erik P. Castle,William J. Catalona,Douglas M. Dahl,John W. Davis,Jonathan I. Epstein,Ruth B. Etzioni,Thomas A. Farrington,George P. Hemstreet,Mark H. Kawachi,Simon P. Kim,Paul H. Lange,Kevin R. Loughlin,William T. Lowrance,Paul Maroni,James L. Mohler,Todd M. Morgan,Kelvin A. Moses,Robert B. Nadler,Michael A. Poch,Charles D. Scales,Terrence M. Shaneyfelt,Marc C. Smaldone,Geoffrey A. Sonn,Preston Sprenkle,Andrew J. Vickers,Robert W. Wake,Dorothy A. Shead,Deborah A. Freedman-Cass +31 more
TL;DR: These NCCN Guidelines Insights summarize the N CCN Prostate Cancer Early Detection Panel's most significant discussions for the 2016 guideline update, which included issues surrounding screening in high-risk populations (ie, African Americans, BRCA1/2 mutation carriers), approaches to refine patient selection for initial and repeat biopsies, and approaches to improve biopsy specificity.